Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037497 | 0.78 | CRHR1 (0.34) | TTR | |
| SCHEMBL12036723 | 0.73 | BPTF (0.33) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL12037050 | 0.71 | L3MBTL1 (0.38) | TTRSMN1; SMN2ALDH1A1MAPK1ESR1 | |
| SCHEMBL6336311 | 0.70 | ALDH1A1 (0.41) | SMN1; SMN2MAPK8NPC1ALDH1A1MAPK1 | |
| SCHEMBL10200515 | 0.70 | TTR (0.46) | TTRSMN1; SMN2MAPK8ALDH1A1MAPK1 | |
| SCHEMBL12453029 | 0.70 | TTR (0.46) | TTRSMN1; SMN2MAPK8ALDH1A1MAPK1 | |
| SCHEMBL12036801 | 0.69 | NOS2 (0.42) | TTRSMN1; SMN2ALDH1A1BACE1ESR1 | |
| SCHEMBL15918803 | 0.68 | GABRA1 (0.39) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL13516712 | 0.68 | NCF1 (0.36) | ALDH1A1ESR1LMNAKMT2AMAPT | |
| SCHEMBL4469982 | 0.68 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPK8NPC1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2536410-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2011103441-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | TTR 467/4885SMN1; SMN2 2306/4885MAPK8 1495/4885 |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | TTR 467/4885SMN1; SMN2 2306/4885MAPK8 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.